Loading
Every dated change on the records linked to Stage III melanoma (after surgery), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Nivolumab plus low-dose ipilimumab did not improve recurrence-free survival over nivolumab alone after resection of stage III to IV melanoma.
2-year EFS 72% vs 49%; HR 0.
A milestone in how this cancer is treated.
12-month recurrence-free survival 70.
10-year RFS 48% vs 32%; DMFS 63% vs 48%.
No melanoma-specific survival benefit; lymphoedema 24% vs 6%.
A milestone in how this cancer is treated.